A parasitic helminth-derived peptide that targets the macrophage lysosome is a novel therapeutic option for autoimmune disease

Immunobiology

Volumn 220, Issue 2, 2015, Pages 262-269

  Alvarado, Raquel ^a   O'Brien, Bronwyn ^a   Tanaka, Akane ^a   Dalton, John P ^b   Donnelly, Sheila ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Autoimmune disease; Cathelicidin; Helminth; Lysosome; Macrophage; Toll like receptor

Indexed keywords

CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATHELICIDIN RELATED ANTIMICROBIAL PEPTIDE; CHLOROQUINE; CRYOPYRIN; HELMINTH DEFENSE MOLECULE; HELMINTH PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; PARASITE ANTIGEN; PEPTIDE;

ACIDIFICATION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CYTOKINE RELEASE; DENDRITIC CELL; ENDOCYTOSIS; ENDOSOME; FASCIOLA HEPATICA; HELMINTHIASIS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYSOSOME; MACROPHAGE; MACROPHAGE ACTIVATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THERAPY WITH HELMINTHS; ANIMAL; AUTOIMMUNE DISEASES; CHEMISTRY; DRUG EFFECTS; HELMINTH; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM;

ANIMALS; ANTIGENS, HELMINTH; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOIMMUNE DISEASES; HELMINTHS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; IMMUNOTHERAPY; LYSOSOMES; MACROPHAGE ACTIVATION; MACROPHAGES; PEPTIDES; SIGNAL TRANSDUCTION;

EID: 84940165162     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.11.008     Document Type: Review

References (90)

1. Ahmad Z., Okafor F., Laughlin T.F. Role of charged residues in the catalytic sites of Escherichia coli ATP synthase. J. Amino Acids 2011, 2011:785741.
2. Amorini A.M., Petzold A., Tavazzi B., Eikelenboom J., Keir G., Belli A., Giovannoni G., Di Pietro V., Polman C., D'Urso S., Vagnozzi R., Uitdehaag B., Lazzarino G. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin. Biochem. 2009, 42(10-11):1001-1006.
3. Andrews S.J. The Life Cycle of Fasciola hepatica, in Fasciolosis 1999, 1-30. CABI, Wallingford. J.P. Dalton (Ed.).
4. Apostolopoulos V., Yuriev E., Lazoura E., Yu M., Ramsland P.A. MHC and MHC-like molecules: structural perspectives on the design of molecular vaccines. Hum. Vaccin 2008, 4(6):400-409.
5. Bainton D.F. The discovery of lysosomes. J. Cell Biol. 1981, 91:66-76.
6. Bever C.T., Garver D.W. Increased cathepsin B activity in multiple sclerosis brain. J. Neurol. Sci. 1995, 131(1):71-73.
7. Beyenbach K.W., Wieczorek H. The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J. Exp. Biol. 2006, 209(Pt 4):577-589.
8. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32(3):305-315.
9. Bright N.A., Gratian M.J., Luzio J.P. Endocytic delivery to lysosomes mediated by concurrent fusion and kissing events in living cells. Curr. Biol. 2005, 15(4):360-365.
10. Calderon B., Carrero J.A., Unanue E.R. The central role of antigen presentation in islets of Langerhans in autoimmune diabetes. Curr. Opin. Immunol. 2014, 26:32-40.
11. Carson M.J., Reilly C.R., Sutcliffe J.G., Lo D. Mature microglia resemble immature antigen-presenting cells. Glia 1998, 22(1):72-85.
12. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silverstri C., Mocchegiani F., Licci A., Skerlavai B., Rocchi M., Saba V., Zanetti M., Scalise G. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 2006, 50(5):1672-1679.
13. Deane J.A., Pisitkun P., Barrett R.S., Feigenbaum L., Town T., Ward J.M., Flavell R.A., Bolland S. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 2007, 27(5):801-810.
14. de Jong B.A., Huizinga T.W., Bollen E.L., Uitdehaag B.M., Bosma G.P., van Buchem M.A., Remarque E.J., Burgmans A.C., Kalkers N.F., Polman C.H., Westendorp R.G. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J. Neuroimmunol. 2002, 126(1-2):172-179.
15. Dombrowski Y., Schauber J. Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp. Dermatol. 2012, 21(5):327-330.
16. Ewald S.E., Lee B.L., Lau L., Wickliffe K.E., Shi G.P., Chapman H.A., Barton G.M. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456(7222):658-662.
17. Fleming J.O. Helminths and multiple sclerosis: will old friends give us new treatments for MS?. J. Neuroimmunol. 2011, 233(1-2):3-5.
18. Gaide O., Hoffman H.M. Insight into the inflammasome and caspase-activating mechanisms. Exp. Rev. Clin. Immunol. 2008, 4(1):61-77.
19. Gangloff M. Different dimerisation mode for TLR4 upon endosomal acidification?. Trends Biochem. Sci. 2012, 37(3):92-98.
20. Garcia-Cattaneo A., Gobert F.X., Müller M., Toscano F., Flores M., Lescure A., Del Nery E., Benaroch P. Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(23):9053-9058.
21. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L., Barrat F.J., Banchereau J., Pascual V. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011, 9(3 (73)):73ra20.
22. Gause W.C., Wynn T.A., Allen J.E. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat. Rev. Immunol. 2013, 13(8):607-614.
23. Ge W., Li D., Gao Y., Cao X. The roles of lysosomes in inflammation and autoimmune diseases. Int. Rev. Immunol. 2014, (Jul). [Epub ahead of print].
24. Grishman E.K., White P.C., Savani R.C. Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes. Pediatr. Res. 2012, 71(6):626-632.
25. Halle A., Hornung V., Petzold G.C., Stewart C.R., Monks B.G., Reinheckel T., Fitzgerald K.A., Latz E., Moore K.J., Golenbock D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9(8):857-865.
26. Harding C.V., Ramachandra L. Presenting exogenous antigen to T cells. Curr. Protoc. Immunol. 2010, 88(16.2):16.2.1-61.2.18.
27. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., Fitzgerald K.A., Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008, 9(8):847-856.
28. Hornung V., Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur. J. Immunol. 2010, 40(3):620-623.
29. Hu Z., Murakami T., Suzuki K., Tamura H., Kuwahara-Arai K., Iba T., Nagaoka I. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. PLoS One 2014, 9(1):e85765.
30. Huang W.X., Huang P., Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult. Scler. 2004, 10(5):482-487.
31. Ip W.K., Sokolovska A., Charriere G.M., Boyer L., Dejardin S., Cappillino M.P., Yantosca L.M., Takahashi K., Moore K.J., Lacy-Hulbert A., Stuart L.M. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J. Immunol. 2010, 184(12):7071-7081.
32. Ishii N.K., Funami M., Tatematsu T., Matsumoto Seya M. Endosomal localization of TLR8 confers distinctive proteolytic processing on human myeloid cells. J. Immunol. 2014, (Oct):1401375. [Epub ahead of print].
33. Jun H.S., Santamaria P., Lim H.W., Zhang M.L., Yoon J.W. Absolute requirement of macrophages for the development and activation of beta-cell cytotoxic CD8+ T-cells in T-cell receptor transgenic NOD mice. Diabetes 1999, 48(1):34-42.
34. Kantarci O.H., Atkinson E.J., Hebrink D.D., McMurray C.T., Weinshenker B.G. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J. Neuroimmunol. 2000, 106(1-2):220-227.
35. Katunuma N., Matsunaga Y., Himeno K., Hayashi Y. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol. Chem. 2003, 384(6):883-990.
36. Kingsbury S.R., Conaghan P.G., McDermott M.F. The role of the NLRP3 inflammasome in gout. J. Inflamm. Res. 2011, 4:39-49.
37. Kobayashi T., Tanaka T., Toyama-Sorimachi N. How do cells optimize luminal environments of endosomes/lysosomes for efficient inflammatory responses?. J. Biochem. 2013, 154(6):491-499.
38. Kuznik A., Bencina M., Svajger U., Jeras M., Rozman B., Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 2011, 186(8):4794-4804.
39. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., Bassett R., Amuro H., Fukuhara S., Ito T., Liu Y.J., Gilliet M. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011, 3(73):73ra19.
40. Lau Y.E., Rozek A., Scott M.G., Goosney D.L., Davidson D.J., Hancock R.E. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun. 2005, 73(1):583-591.
41. Lee S., Silverman E., Bargman J.M. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat. Rev. Nephrol. 2011, 7:718-729.
42. Liu B., Shen Y., Xiao K., Tang Y., Cen L., Wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol. Res. 2012, 34(2):163-171.
43. Luzio J.P., Pryor P.R., Bright N.A. Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 2007, 8(8):622-632.
44. Maehr R., Mintern J.D., Herman A.E., Lennon-Dumenil A.M., Mathis D., Benoist C., Ploegh H.L. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. J. Clin. Invest. 2005, 115(10):2934-2943.
45. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune diseases. Nat. Rev. Immunol. 2006, 6:823-835.
46. Martinson J.A., Montoya C.J., Usuga X., Ronquillo R., Landay A.L., Desai S.N. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob. Agents Chemother. 2010, 54(2):871-881.
47. Masters S.L., Dunne A., Subramanian S.L., Hull R.L., Tannahill G.M., Sharp F.A., Becker C., Franchi L., Yoshihara E., Chen Z., Mullooly N., Mielke L.A., Harris J., Coll R.C., Mills K.H., Mok K.H., Newsholme P., Nunez G., Yodoi J., Kahn S.E., Lavelle E.C., O'Neill L.A. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 2010, 11(10):897-904.
48. Mathis D., Vence L., Benoist C. Beta-cell death during progression to diabetes. Nature 2001, 414(6865):792-798.
49. McSorley H.J., Maizels R.M. Helminth infections and host immuneregulation. Clin. Microbiol. Rev. 2012, 25:585-608.
50. Meyers A.J., Shah R.R., Gottlieb P.A., Zipris D. Altered Toll-like receptor signaling pathways in human type 1 diabetes. J. Mol. Med. (Berl.) 2010, 88(12):1221-1231.
51. Mindell J.A. Lysosomal acidification mechanisms. Annu. Rev. Physiol. 2012, 74:69-86.
52. Mohan J.F., Levisetti M.G., Calderon B., Herzog J.W., Petzold S.J., Unanue E.R. Unique autoreactive T cells recognize insulin peptides generated within the islets of Langerhans in autoimmune diabetes. Nat. Immunol. 2010, 11(4):350-354.
53. Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., Powers J.P., Bryan J., Brinkman F.S., Hancock R.E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 2006, 176(4):2455-2464.
54. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., McNeish J.D., Eastman S.E., Howard E.D., Clarke S.R., Rosloniec E.F., Elliott E.A., Rudensky A.Y. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10(2):207-217.
55. O'Brien B.A., Geng X., Orteu C.H., Huang Y., Ghoreishi M., Zhang Y., Bush J.A., Li G., Finegood D.T., Dutz J.P. A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J. Autoimmun. 2006, 26(2):104-115.
56. Ohkuma S., Moriyama Y., Takano T. Identification and characterization of a proton pump on lysosomes by fluorescein-isothiocyanate-dextran fluorescence. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:2758-2762.
57. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008, 9(12):1407-1414.
58. Pinheiro da Silva F.R.L., Gallo F., Nizet V. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunol. Cell Biol. 2009, 87(6):496-500.
59. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312(5780):1669-1672.
60. Pochet S., Tandel S., Querriere S., Tre-Hardy M., Garcia-Marcos M., De Lorenzi M., Vandenbranden M., Marino A., Devleeschouwer M., Dehaye J.P. Modulation by LL-37 of the responses of salivary glands to purinergic agonists. Mol. Pharmacol. 2006, 69(6):2037-2046.
61. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., Eklund K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5(7):e11765.
62. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat. Immunol. 2012, 13(4):333-342.
63. Reddy L.G., Shi Y., Kutchai H., Filoteo A.G., Penniston J.T., Thomas D.D. An autoinhibitory peptide from the erythrocyte Ca-ATPase aggregates and inhibits both muscle Ca-ATPase isoforms. Biophys. J. 1999, 76(6):3058-3065.
64. Robinson M.W., Donnelly S., Hutchinson A.T., To J., Taylor N.L., Norton R.S., Perugini M.A., Dalton J.P. A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides. PLoS Pathog. 2011, 7(5):e1002042.
65. Robinson M.W., Alvarado R., To J., Hutchinson A.T., Dowdell S.N., Lund M., Turnbull L., Whitchurch C.B., O'Brien B.A., Dalton J.P., Donnelly S. A helminth cathelicidin-like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal vATPase. FASEB J. 2012, 26(11):4614-4627.
66. Robinson M.W., Dalton J.P., O'Brien B.A., Donnelly S. Fasciola hepatica: the therapeutic potential of a worm secretome. Int. J. Parasitol. 2013, 43(3-4):283-291.
67. Robinson M.W., Donnelly S., Dalton J.P. Helminth defence molecules-immunomodulators designed by parasites!. Front. Microbiol. 2013, 4:296.
68. Rossi A., Deveraux Q., Turk B., Sali A. Comprehensive search for cysteine cathepsins in the human genome. Biol. Chem. 2004, 38(5):363-372.
69. Saegusa K., Ishimaru N., Yanagi K., Arakaki R., Ogawa K., Saito I., Katunuma N., Hayashi Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest. 2002, 110(3):361-369.
70. Satoh J., Lee Y.B., Kim S.U. T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res. 1995, 704(1):92-96.
71. Seil M., Kabre E., Nagant C., Vandenbranden M., Fontanils U., Marino A., Pochet S., Dehaye J.P. Regulation by CRAMP of the responses of murine peritoneal macrophages to extracellular ATP. Biochim. Biophys. Acta 2010, 1798(3):569-578.
72. Settembre C., Fraldi A., Medina D.L., Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 2013, 14(5):283-296.
73. Singh J.A., Cameron D.R. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults - an update. J. Manage. Care Pharm. 2012, 18(4 Supp C):S1-S18.
74. Smith M.E. Phagocytosis of myelin in demyelinative disease: a review. Neurochem. Res. 1999, 24(2):261-268.
75. Subramanian S., Tus K., Li Q.Z., Wang A., Tian X.H., Zhou J., Liang C., Bartov G., McDaniel L.D., Zhou X.J., Schultz R.A., Wakeland E.K. Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(26):9970-9975.
76. Talloczy Z., Martinez J., Joset D., Ray Y., Gacser A., Toussi S., Mizushima N., Nosanchuk J.D., Goldstein H., Loike J., Sulzer D., Santambrogio L. Methamphetamine inhibits antigen processing, presentation, and phagocytosis. PLoS Pathog. 2008, 4(2):e28.
77. Thivierge K., Cotton S., Schaefer D.A., Riggs M.W., To J., Lund M.E., Robinson M.W., Dalton J.P., Donnelly S.M. Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, anti-microbial and anti-protozoan activities imply a specific adaptation to immune modulation. PLoS Negl. Trop. Dis. 2013, 7(7):e2307.
78. Thome R., Issayama L.K., DiGangi R., Bombeiro A.L., da Costa T.A., Ferreira I.T., de Oliveira A.L., Verinaud L. Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis. Immunol. Cell Biol. 2014, 92(2):124-132.
79. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 2010, 10(3):210-215.
80. van der Laan L.J., Ruuls S.R., Weber K.S., Lodder I.J., Dopp E.A., Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide. J. Neuroimmunol. 1996, 70(2):145-152.
81. Watts C. The endosome-lysosome pathway and information generation in the immune system. Biochim. Biophys. Acta. 2012, 1824(1):14-21.
82. Weber K., Schilling J.D. Lysosomes integrate metabolic-inflammatory cross-talk in primary macrophage inflammasome activation. J. Biol. Chem. 2014, 289(13):9158-9171.
83. Weinstock J.V. Autoimmunity: the worm returns. Nature 2012, 491:183-185.
84. Williams K., Ulvestad E., Waage A., Antel J.P., McLaurin J. Activation of adult human derived microglia by myelin phagocytosis in vitro. J. Neurosci. Res. 1994, 38(4):433-443.
85. Yamada A., Ishimaru N., Arakaki R., Katunuma N., Hayashi Y. Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity. PLoS One 2010, 5(9):e12894.
86. Yin Y., Pastrana J.L., Li X., Huang X., Mallilankaraman K., Choi E.T., Madesh M., Wang H., Yang X.F. Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front. Biosci. (Landmark Ed) 2013, 18:638-649.
87. Yoshida H., Okabe Y., Kawane K., Fukuyama H., Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 2005, 6(1):49-56.
88. Zaccone P., Fehervari Z., Phillips J.M., Dunne D.W., Cooke A. Parasitic worms and inflammatory diseases. Parasite Immunol. 2006, 28(10):515-523.
89. Zhang T., Maekawa Y., Hanba J., Dainichi T., Nashed B.F., Hisaeda H., Sakai T., Asao T., Himeno K., Good R.A., Katunuma N. Lysosomal cathepsin B plays an important row in antigen processing, while cathepsin D is involved in degradation of the invariant chain in ovalbumon-immunized mice. Immunology 2000, 100(1):13-20.
90. Zhang Y., O'Brien B.A., Trudeau J., Tan R., Santamaria P., Dutz J.P. In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J. Immunol. 2002, 168(3):1466-1472.